Nautilus Biotechnology, Inc. (NAUT)
NASDAQ: NAUT · Real-Time Price · USD
2.510
+0.040 (1.62%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Nautilus Biotechnology Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -59 | -70.78 | -63.68 | -57.92 | -50.32 | |
| Depreciation & Amortization | 6.47 | 6.44 | 5.71 | 3.42 | 2.84 | |
| Loss (Gain) From Sale of Assets | - | - | - | - | 0.14 | |
| Asset Writedown & Restructuring Costs | - | 0.76 | - | - | - | |
| Loss (Gain) From Sale of Investments | -1.42 | -2.8 | -2.66 | -0.89 | 0.18 | |
| Stock-Based Compensation | 6.84 | 12.7 | 12.14 | 10.38 | 7.93 | |
| Change in Accounts Payable | -0.07 | -0.58 | 0.39 | -0.56 | 1.26 | |
| Change in Other Net Operating Assets | -3.52 | -4.88 | -3.61 | -0.23 | -1.28 | |
| Operating Cash Flow | -50.7 | -59.15 | -51.71 | -45.81 | -39.24 | |
| Capital Expenditures | -1.28 | -2.88 | -2.44 | -2.32 | -2.27 | |
| Investment in Securities | 36.5 | 69.13 | -41.29 | -23.42 | -136.7 | |
| Investing Cash Flow | 35.22 | 66.25 | -43.74 | -25.74 | -138.96 | |
| Issuance of Common Stock | 0.21 | 1.14 | 0.37 | 0.56 | 335.58 | |
| Other Financing Activities | - | - | - | - | -8.13 | |
| Financing Cash Flow | 0.21 | 1.14 | 0.37 | 0.56 | 327.45 | |
| Net Cash Flow | -15.26 | 8.25 | -95.08 | -70.98 | 149.24 | |
| Free Cash Flow | -51.97 | -62.03 | -54.15 | -48.13 | -41.51 | |
| Free Cash Flow Per Share | -0.41 | -0.49 | -0.43 | -0.39 | -0.49 | |
| Levered Free Cash Flow | -28.78 | -36.23 | -32.09 | -27.58 | -22.33 | |
| Unlevered Free Cash Flow | -28.78 | -36.23 | -32.09 | -27.58 | -22.33 | |
| Change in Working Capital | -3.58 | -5.46 | -3.22 | -0.79 | -0.02 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.